Viking Therapeutics, Inc. Convertible Notes Payable, Current
Viking Therapeutics, Inc. (VKTX) had Convertible Notes Payable, Current of $3.72 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ConvertibleNotesPayableCurrent · last filed 2019-03-13
- 2018-03-31: Convertible Notes Payable, Current $3.72M.
- 2017-12-31: Convertible Notes Payable, Current $3.45M; Convertible Notes Payable, Current as first filed $3.45M.
- 2017-09-30: Convertible Notes Payable, Current $3.18M.
- 2017-06-30: Convertible Notes Payable, Current $3.05M.
| Period end | Convertible Notes Payable, Current | Convertible Notes Payable, Current as first filed |
|---|---|---|
| 2018-03-31 | $3.72M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.45M 10-K · filed 2019-03-13 | $3.45M 10-K · filed 2018-03-07 |
| 2017-09-30 | $3.18M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $3.05M 10-Q · filed 2017-08-09 | |
| 2016-12-31 | $3.27M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $2.83M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $2.38M 10-Q · filed 2016-08-11 | |
| 2015-09-30 | $1.91M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $1.67M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $310.35K 10-Q · filed 2015-06-12 | |
| 2014-12-31 | $304.27K 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |